Document is current
Any future updates will be listed below
-
Authors
Churchill, Grant C.
Strupp, Michael
Factor, Cailley
Bremova-Ertl, Tatiana
Factor, Mallory
Patterson, Marc C.
Platt, Frances M.
Galione, Antony
-
Funding
Funding for this research was provided by:
IntraBio
- License Information
-
More Information
Article History
Received: 12 May 2021
Accepted: 23 July 2021
First Online: 4 August 2021
Competing interests
: I have read the journal's policy and the authors of this manuscript have the following competing interests: MS is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker’s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, Merck, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. He is a shareholder of IntraBio. He acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion. MF is a co-founder, shareholder, and Chairman of IntraBio. MP is a shareholder of IntraBio and has received consulting fees, honoraria, and research grants from Actelion Pharmaceuticals Ltd. and Biomarin. TBE received honoraria for lecturing from Actelion and Sanofi Genzyme. CF is a consultant to IntraBio. GCC, AG and FP are cofounders, shareholders and consultants to IntraBio. IntraBio Ltd is the applicant for patents WO2018229738 (Treatment For Migraine), WO2017182802 (Acetyl-Leucine Or A Pharmaceutically Acceptable Salt Thereof For Improved Mobility And Cognitive Function), WO2019078915 and WO2018029658 (Therapeutic Agents For Neurodegenerative Diseases), WO2018029657 (Pharmaceutical Compositions And Uses Directed To Lysosomal Storage Disorders), and WO2019079536 (Therapeutic Agents For Improved Mobility And Cognitive Function And For Treating Neurodegenerative Diseases And Lysosomal Storage Disorders).
